OVERVIEW

Clinical Issues in Rheumatoid Arthritis: Debates & Discussions on the Evolving Role of JAK Inhibitors is organized by Global Academy for Medical Education, LLC. This Online CME Conference has been approved for a maximum of 1.5 AMA PRA Category 1 Credits™.

Who should attend?
The educational intention of this activity addresses the essentials of clinical rheumatologists and specialist nurse practitioners (NPs), physician assistants (PAs), and nurses who handle patients with rheumatoid arthritis (RA).

Release date: Aug 14, 2019
Valid through: Aug 14, 2020.

What is the significance of Clinical Issues in Rheumatoid Arthritis: Debates & Discussions on the Evolving Role of JAK Inhibitors?

Course Description:
This digital CME program, titled “Clinical Issues in Rheumatoid Arthritis: Debates and Discussions on the Evolving Role of JAK Inhibitors,” has been produced from the proceedings of an online symposium held during the American College of Rheumatology’s (ACR) 2019 State-of-the-Art (SOTA) Clinical Symposium. In this activity, an expert panel of rheumatologists reviews and debate the latest insights regarding Janus kinase (JAK) activation in RA immunopathology, recent clinical trial data on the efficacy and safety of current and emerging JAK inhibitors, and the evolving roles of this disease-modifying antirheumatic drug (DMARD) class in day-to-day clinical practice.

What are the objectives of Clinical Issues in Rheumatoid Arthritis: Debates & Discussions on the Evolving Role of JAK Inhibitors?

Learning Objectives:
After completing this CME webcast, the participant should be better able to:
• Explain the roles of JAK/signal transducer and activator of transcription (STAT) signaling in immune responses and homeostasis, including contributions to the immunopathogenesis of RA
• Examine the clinical profiles of current and developing JAK inhibitors, including implications of enzyme specificity and evidence for efficacy and safety in RA
• Combine JAK inhibitors into RA-treatment algorithms based on guideline recommendations, current clinical trial data, and patient preference.